



Contacts: Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson, Inc.  
(310) 279-5963

## Somaxon Pharmaceuticals to Present at the Merriman Curhan Ford 2006 Investor Summit

**SAN DIEGO, CA – September 13, 2006** – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the Merriman Curhan Ford 2006 Investor Summit at the Mark Hopkins Hotel, in San Francisco, on Monday, September 18, 2006, at 10:45 a.m. Pacific Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at [www.somaxon.com](http://www.somaxon.com). The webcast will be archived and accessible for at least 14 days.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR™ (doxepin HCl), is in Phase 3 clinical trials for the treatment of insomnia. Nalmefene HCl is in a Phase 2/3 clinical trial for pathological gambling and has completed a pilot Phase 2 trial for smoking cessation. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

###